Antibiotic Incentives: A Warm-up for Big Stakes Fight over Follow-on Biologics

Drug development incentives for neglected diseases, antibiotics and enantiomers in the Senate's drug safety/user fee bill do not appear to create niches for blockbuster commercial products, but they are not insignificant. They are important as much as markers that Congress, despite the new Democratic majority, is still open to certain types of incentives for the drug industry.